Le Lézard
Classified in: Health
Subject: SVY

Global $100+ Billion Cancer Immunotherapies Market to 2024 - 3,863 Cancer Immunotherapy Products in the Pipeline


DUBLIN, Aug. 17, 2018 /PRNewswire/ --

The "Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient's immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

Scope

Key Topics Covered:

1 Tables & Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Overview of Key Indications and Symptoms
2.3 Diagnosis
2.4 Etiology and Pathophysiology
2.5 Epidemiology
2.6 Prognosis
2.7 Treatment

3 Key Marketed Products
3.1 Overview
3.2 Revlimid (lenalidomide) - Celgene
3.3 Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb
3.4 Keytruda (pembrolizumab) - Merck & Co.
3.5 Tecentriq (atezolizumab) - Roche
3.6 Darzalex (daratumumab) - Johnson & Johnson
3.7 Imfinzi (durvalumab) - AstraZeneca/Celgene
3.8 Gardasil/Gardasil 9 (human papillomavirus vaccine) - Merck & Co.
3.9 Pomalyst/Imnovid (pomalidomide) - Celgene
3.10 Yescarta (axicabtagene ciloleucel) - Gilead Sciences
3.11 Gazyva (obinutuzumab) - Roche
3.12 Yervoy (ipilimumab) - Bristol-Myers Squibb
3.13 Rituxan (rituximab) - Roche/Biogen
3.14 Kymriah (tisagenlecleucel) - Novartis

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.5 Late-Stage Drugs of the Developmental Pipeline
4.5.1 Lisocabtagene maraleucel - Juno Therapeutics/Celgene
4.5.2 Durvalumab plus Tremelimumab - AstraZeneca
4.5.3 Tremelimumab - AstraZeneca
4.5.4 Cemiplimab - Regeneron/Sanofi
4.5.5 Epacadostat - Incyte Corp
4.5.6 Axalimogene filolisbac - Advaxis

5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Immune Checkpoint Proteins
5.3.2 Tumor Associated Antigens
5.3.3 Cytokine Signaling
5.3.4 HPV

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Celgene - Revlimid to Maintain Celgene's Position as Market Leader
6.1.2 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth
6.1.3 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies
6.1.4 Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan
6.1.5 AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence
6.1.6 Johnson & Johnson - Darzalex Key to Strong Growth
6.1.7 Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue
6.1.8 AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024
6.1.9 Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta
6.1.10 Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters
6.2 Market and Pipeline Company Landscape

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Deal Value and Year
7.1.2 Deals by Indication and Deal Value
7.1.3 Deals by Stage of Development and Deal Value
7.1.4 Deals by Molecule Type, Molecular Target and Deal Value
7.1.5 Table for Licensing Deals with Disclosed Deal Value
7.2 Co-development Deals
7.2.1 Deals by Region, Deal Value and Year
7.2.2 Deals by Indication and Deal Value
7.2.3 Deals by Stage of Development and Deal Value
7.2.4 Deals by Molecule Type, Molecular Target and Deal Value
7.2.5 Table for Co-development Deals with Disclosed Deal Value

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/wpmw77/global_100?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...

at 10:00
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.A...

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...



News published on and distributed by: